secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001104659-24-087301
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Q2 net loss $9.4M; FDA acceptance of CARDAMYST NDA with PDUFA March 2025
--------------------------------------------------------------------------------

- FDA accepted CARDAMYST (etripamil) NDA for PSVT; PDUFA target date set for March 2025.
- Cash and equivalents $83.3M as of June 30, 2024, expected to fund operations into 2026.
- Q2 2024 net loss $9.4M vs $16.0M in Q2 2023; R&D expenses down to $2.8M from $8.6M.
- Stuart Duty and Andrew Saik appointed as independent directors to the board.
- Phase 3 AFib-RVR trial design ongoing; enrollment planned for first half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465924087301/0001104659-24-087301-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465924087301/tm2421158d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-087301

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer